Expanding Veterans’ Access to Emerging Treatments Act
Sponsored By: Representative Bergman, Jack [R-MI-1]
In Committee
Summary
Expands veterans' access to innovative and emerging treatments, including psychedelic- and entactogenic-assisted therapies. This bill would direct the Department of Veterans Affairs to create an investigational research and extended access program to treat veterans with unmet medical needs using those therapies in a way that follows federal law.
Show full summary
- Veterans with chronic pain, PTSD, depression, traumatic brain injury, or substance use disorders could be eligible to join clinical trials or be considered for compassionate or extended access to specified therapies.
- The VA would have to start the program within 90 days and appoint a lead administrator within 60 days to run it.
- The VA could run clinical trials, use existing VA funds to support research, and study treatments named in the bill such as psilocybin, MDMA, ketamine, and ibogaine, plus certain investigational devices. The Secretary must report to congressional committees within one year and review the program within two years to decide whether to extend or end it.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
More VA access to experimental treatments
If enacted, the VA would have 90 days to set up an investigational research program for veterans with listed conditions. The VA would name a lead administrator within 60 days, run clinical trials, and create compassionate or extended access pathways for eligible veterans. The VA could use existing VA funds to support trials and must review the program within two years and may extend or end it. The bill would define "innovative treatments" to include 3,4-Methylenedioxy-methamphetamine; 5-Methoxy-N,N-dimethyltryptamine; 5-Methoxy-2-aminoindane; ibogaine; ketamine; and psilocybin, and would list covered conditions such as anxiety, chronic pain, depression, PTSD, substance use disorders (including alcohol and cocaine), and traumatic brain injury; the Secretary could add other treatments or conditions. All activities would have to follow applicable federal law on investigational products and controlled substances.
Sponsors & CoSponsors
Sponsor
Bergman, Jack [R-MI-1]
MI • R
Cosponsors
Rep. Correa, J. Luis [D-CA-46]
CA • D
Sponsored 1/15/2026
Crenshaw
TX • R
Sponsored 2/11/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov